首页> 外文期刊>Infection and Drug Resistance >A Real-World Study Comparing Various Antimicrobial Regimens for Bloodstream Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli in a Tertiary Hospital, Shanghai, China, from 2010 to 2017
【24h】

A Real-World Study Comparing Various Antimicrobial Regimens for Bloodstream Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli in a Tertiary Hospital, Shanghai, China, from 2010 to 2017

机译:2010年至2017年上海市上海市上海市抗菌革兰氏菌造成的血流感染各种抗微生物治疗血管感染的各种抗菌药物的真实研究

获取原文
       

摘要

Background: We conducted a real-world analysis of the effectiveness of different antibiotic regimens for bloodstream infections (BSIs) caused by carbapenem-resistant gram-negative bacilli (CR-GNB) in a Chinese population. Methods: A retrospective observational study was conducted between January 2010 and December 2017. Patients with BSIs caused by CR-GNB confirmed by in vitro susceptibility tests were enrolled, and patient medical record data on antimicrobial agents and microbiological and clinical outcomes were extracted. Results: A total of 175 individuals were included; 127 individuals (72.6%) received combination therapy (two or more antibiotics), while 48 individuals (27.4%) received monotherapy (single antibiotic). The all-cause 28-day mortality was 20.0%. Treatment success or presumed success rates were very similar between the monotherapy and combination therapy groups (58.3% versus 59.1%; P = 0.931). Combination therapy had a higher success rate trend than monotherapy in septic shock patients (40.7% versus 18.2%; P = 0.268). Improved therapeutic effects were observed in the active agent-containing group, although the differences were not significant. Conclusion: Combination therapy likely has better therapeutic effects on critical BSIs caused by CR-GNB than monotherapy. Choosing a proper active agent in an antimicrobial regime is relatively crucial to the ultimate treatment outcome.
机译:背景:我们对中国人群中耐肉豆蔻革兰阴性杆菌(Cr-GNB)引起的血流感染(BSI)引起的不同抗生素方案的有效性进行了真实的分析。方法:2010年1月至2017年12月进行了回顾性观察研究。注册了通过体外敏感性试验证实的CR-GNB引起的BSI患者,提取患者对抗微生物剂和微生物和微生物和临床结果的患者。结果:共有175人; 127个个体(72.6%)接受组合治疗(两种或更多种抗生素),而48个个体(27.4%)接受单药治疗(单抗生素)。全部导致28天死亡率为20.0%。治疗成功或假定的成功率在单疗法和联合治疗组之间非常相似(58.3%对59.1%; P = 0.931)。联合治疗的成功率较高,而不是脓毒症休克患者的单一疗法(40.7%对18.2%; P = 0.268)。在含活性剂的基团中观察到改善的治疗效果,尽管差异不显着。结论:组合治疗可能对CR-GNB引起的临危BSI具有比单一疗法的临危BSI更好的治疗效果。在抗微生物制度中选择适当的活性剂对最终的治疗结果相对至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号